Current Editions
Early-stage venture funding dries up for U.S. cell and gene therapy biotechs
As seed and series A funding falls off a cliff for U.S. cell and gene therapy start-ups, China becomes a bright spot
Product Development
Product Development
Inside precision oncology’s next chapter with Bill Hinshaw
Novartis veteran and Fore CEO on diagnostics, fragmentation, and the operational realities behind today’s precision paradigm: The BioCentury Show
Data Byte
FDA approved five NMEs in November
Two biotechs received their first product approvals in a month that also delivered the first pertuzumab biosimilar
Regulation
Naming Makary loyalist CDER head will prompt staff departures, ease restraints on FDA leaders
Latest churn in leadership at FDA has Høeg replacing Pazdur, long-serving director Michele sidelined
BioCentury ISSN 1097-7201